Near-infrared spectroscopy in compliance with pharma regulations

Importance of the Topic

Near-infrared spectroscopy (NIRS) has emerged as a critical secondary analytical tool in pharmaceutical manufacturing due to its speed, non-destructive nature, and minimal sample preparation. Recognized by major pharmacopoeias and endorsed by regulatory frameworks such as FDA’s PAT initiative, EMA guidelines, and ICH Q8–Q10, NIRS supports the industry’s shift toward built-in quality and real-time process monitoring. Its ability to deliver both chemical and physical sample information in seconds makes it indispensable for ensuring product safety, efficacy, and regulatory compliance.

Objectives and Overview

This white paper by Metrohm outlines how its NIRS solutions fulfill pharmaceutical regulatory requirements and streamline quality assurance workflows. It presents an overview of NIRS applications across the product lifecycle—from raw material identification to finished-product quality control—and describes the validation procedures needed for software, instruments, and analytical methods. Key aims include demonstrating compliance with relevant guidelines and showcasing the practical benefits of Metrohm’s hardware and software platforms.

Methodology and Instrumentation

NIRS relies on the measurement of near-infrared absorbance to derive qualitative and quantitative parameters. Typical workflows involve:

• Minimal or no sample preparation, preserving sample integrity.
• Rapid acquisition of spectra to assess multiple attributes in one measurement.
• Chemometric modeling for identity testing, content uniformity, moisture analysis, and more.

Instrument qualification follows USP<1058> protocols, covering Installation Qualification (IQ), Operational Qualification (OQ), and Performance Qualification (PQ) to ensure wavelength accuracy, photometric performance, and long-term stability. Software validation meets FDA 21 CFR Part 11 and EU Annex 11 requirements for electronic records and signatures. Method validation adheres to industry standards for specificity, accuracy, precision, and robustness, as detailed in USP<1119> and other guidelines.

Instrumentation Used

Metrohm NIRS portfolio includes:

• XDS MasterLab spectrometers for high-resolution laboratory analysis.
• Inline/online analyzers for real-time monitoring of processes such as granulation, drying, and bioreactor cell density.
• Atline/offline probe systems for blend homogeneity and intermediate assays.
• Vision Air software for data acquisition, spectrum management, and regulatory-compliant reporting.

Main Results and Discussion

Applications of Metrohm NIRS systems demonstrate:

• Efficient incoming raw material inspection to verify identity and conformity under FDA CFR 211.84 and EU GMP Chapter 8.
• Inline monitoring that reduces out-of-specification batches and rework by tracking critical parameters in real time.
• Atline/offline assays optimizing granulation endpoints and blend uniformity, improving process understanding and throughput.
• Non-destructive testing of finished dosage forms—including tablets in blisters—providing rapid content and purity assessments.

These case studies underscore the high return on investment achieved through shortened analysis cycles and enhanced process control.

Benefits and Practical Applications of the Method

NIRS delivers numerous advantages in pharmaceutical settings:

• Significant time savings compared to wet-chemical assays.
• Non-invasive testing that preserves valuable samples.
• Simultaneous multi-parameter analysis (e.g., moisture, potency, blend uniformity).
• Seamless integration into PAT frameworks for continuous quality verification.

Future Trends and Potential Applications

Emerging directions for NIRS in the pharmaceutical industry include:

• Integration with digital manufacturing and Industry 4.0 infrastructures for end-to-end data interoperability.
• Advanced chemometric and machine-learning models to improve predictive accuracy and robustness.
• Expanded use in personalized medicine formulations and rapid release testing.
• Harmonized global regulatory acceptance streamlining method transfers across sites.

Conclusion

NIRS is a proven, regulatory-compliant analytical technology that enhances quality assurance throughout pharmaceutical production. Metrohm’s comprehensive solutions—including validated instruments, software, and application support—enable efficient implementation of NIRS methods that meet stringent regulatory demands while delivering tangible process efficiencies.

References

1. Ciurczak E.W., Igne B. Pharmaceutical and Medical Applications of Near-Infrared Spectroscopy. CRC Press, 2015.
2. Broad N. et al. Guidelines for Development and Validation of Near-Infrared Methods in Pharma. Handbook of Vibrational Spectroscopy, 2002.
3. Application Bulletin AB-410. NIR for Raw Material Identification.
4. Application Bulletin AB-410. Identification of Pharmaceutical Raw Materials.
5. Mattes R. et al. Monitoring Viable Cell Density in Bioreactors Using NIRS. BioProcessing Journal, 2010.
6. Application Note AN-NIR-016. NIR for Single-Pot Granulator Monitoring.
7. Application Note AN-NIR-021. Monitoring Purity of Recovered Solvents with NIRS.
8. Application Bulletin AB-358. Residual Moisture Analysis in Lyophilized Products.
9. Application Note AN-NIR-014. NIR for Pharmaceutical Mixing Studies.
10. Application Note AN-NIR-002. Single Tablet Analysis with XDS RapidContent.
11. Application Note AN-NIR-017. Predictive Model for API Release.
12. Application Note AN-NIR-018. NIR Assay and Content Uniformity of Tablets.
13. Application Note AN-NIR-001. Solid-State Standard Additions for Dosage Forms.
14. USP<1119> Near-Infrared Spectroscopy, USP 39 (2016).
15. Metrohm White Paper WP-017EN. Near-Infrared Spectroscopy in Compliance with Pharma Regulations, 2017.